Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson’s Disease

<div>Patient’s preferences and choices in the end of the trial. (a) Preferences: in response to the final preference questionnaire, 27% (<i>n</i> = 12) of the patients preferred the once-daily regimen, 41% (<i>n</i> = 18) preferred the twice-daily regimen, and 32% (<i>n</i> = 14) did not have a preference. (b) Patient’s choices in the end of the trial and reasons. In response to the final choices questionnaire, 32% (<i>n</i> = 14) of the patients wanted to take the once-daily regimen, 57% (<i>n</i> = 25) chose the twice-daily regimen, and 11% (<i>n</i> = 5) wanted to revert to previous dopamine agonists.</div>

Parkinson’s Disease

fig3

Figure 3

Figure 3: Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson’s Disease 